FindTrial
Sign In

Effectiveness and safety of Memantine in reducing nerve pain in people with Diabetes

Efficacy and safety of memantine as an add-on therapy in diabetic peripheral neuropathy: a prospective, open-label, randomized clinical trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110766
Enrollment
100
Registered
2026-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: Diabetic Peripheral Neuropathy: TABLET MEMANTINE 10MG TWICE A DAY FOR 12 WEEKS Control Intervention1: Diabetic Peripheral Neuropathy: TABLET CARBAMAZEPINE 200MG ONCE A DAY FOR 12 WEEKS

Sponsors

ANUJA DURAIRAJ
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Type 2 DM on Insulin and/or Oral anti-diabetic therapy. 2. Clinically diagnosed with neuropathy using diagnostic tests (Monofilament test & Biothesiometry) at the Diabetology Clinic in our hospital 3. Participants exhibiting neuropathic pain scoring more than 4 on Neuropathic Pain Diagnostic Questionnaire (DN4)

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes Mellitus 2. Patients with a history of allergy/ hypersensitivity to the study drug. 3. Patients with a documented history of hereditary neuropathies/ drug-induced neuropathies. 4. Patients on long-term corticosteroid therapy. 5. History of cardiovascular disease- cardiac failure, angina 6. Patients with renal failure

Design outcomes

Primary

MeasureTime frame
Reduction in scores of DN4 and MNSITimepoint: 0,4,8,12 weeks—

Secondary

MeasureTime frame
Assessment of safety and tolerabilityTimepoint: 4,8,12 weeks—

Countries

India

Contacts

Public ContactDr Sasikala G

Govt. Kilpauk Medical College

sasikala.shri@gmail.com9952579804

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026